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Over the last 50 years, routine lipid parameters for risk prediction of cardiovascular disease 
(CVD) have not changed: clinical assays still rely on simple biochemical measurements of 
total triglycerides, total cholesterol and high-density lipoprotein cholesterol (HDL-C). Low-
density lipoprotein cholesterol (LDL-C) is not always measured but calculated from non-HDL-
C. Further, standard lipid tests quantify the cholesterol or triglyceride content of 
lipoproteins, without providing size-specific lipoprotein particle information. By contrast, 
nuclear magnetic resonance spectroscopy (NMR) provides a rapid method for distinguishing 
and quantifying a wide range of lipoprotein subclasses. Upon exposure to a magnetic field, 
distinct lipoprotein subclasses emit a unique signal that is directly proportional to their 
concentration. Although NMR lacks sensitivity when compared with mass spectrometry, it 
can be used to analyse the lipid composition of lipoprotein subclasses (1,2).  
In this edition of the Journal, NMR-based findings from The China Kadoorie Biobank Study 
contribute to refining the quantitative and qualitative features of atherogenic lipid profiles 
(3). Very low-density lipoprotein (VLDL) particle concentrations were at least as strongly 
associated with myocardial infarction (MI) and ischaemic stroke (IS) as LDL particles.  
Further, triglycerides (TGs) were more consistently related with MI and IS across the entire 
spectrum of lipoprotein subfractions than cholesterol, and VLDL and remnant cholesterol 
outperformed LDL-C in CVD risk prediction in this Chinese population characterized with low 
mean LDL-C levels (85 mg/dL in the control group).  
A causal role for remnant cholesterol in TG-rich lipoproteins such as VLDL has previously 
been suggested by meta-analysis and large-scale Mendelian Randomization studies (4,5). 
Similarly, mass spectrometry-based proteomics in the Bruneck Study ranked apoCIII, apoCII 
and apoE - three VLDL-associated apolipoproteins - as first to third with regards to CVD risk 
prediction (6). However, these data must be interpreted in the context of the widespread 
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use of statins for primary prevention in this cohort. Emerging studies suggest that cause for 
MI is shifting from plaque ruptures to plaque erosions, possibly due to the widespread use of 
LDL-C lowering therapies (7,8). With low LDL-C levels, the relative contribution of TG-rich 
lipoproteins to CVD risk may increase. 
The China Kadoorie Biobank Study offers additional remarkable insights. First, the data 
contradict the conventional, yet outdated view that lipids are predominantly a risk factor for 
MI and are only a weak predictor for IS. In fact, the associations of lipoprotein particles with 
MI and IS were highly concordant, and their magnitude was only marginally lower for IS. This 
is supported by other studies that obtained similar findings for MI and IS, i.e. by measuring 
the plasma lipidome (9) or apolipoproteins like lipoprotein (a) (10-12). The most recent 
meta-analysis of LDL-C lowering therapies yielded a risk reduction of 24% for MI and 19% for 
overall stroke for more-intensive versus less-intensive therapy (13). The randomized 
controlled trials (RCTs) for PCSK9 inhibition and ezetimibe therapy but not cholesterylester 
transfer protein inhibition with anacetrapib reported benefits of lipid-lowering therapy for IS 
similar to or even higher than for MI (14-17). Taken together, these findings are consistent 
with the notion that lipids promote atherosclerosis systemically and that atherosclerosis is a 
main underlying cause for IS across its major subtypes. The pathogenetic relevance of lipids 
is obvious for IS as a downstream manifestation of atherosclerosis in extra- or intracranial 
large arteries, one of the main causes of stroke in China. It is also plausible for small vessel 
stroke. Small vessel strokes commonly arise from plaques at the orifice of the penetrating 
artery rather than from lipohyalinosis. The pathogenic relevance, however, may also extend 
to cardioembolic stroke and Embolic Stroke of Undetermined Source (ESUS). Stiffening of 
the aorta due to atherosclerosis and subsequent loss of the Windkessel function may elicit a 
diastolic backwards flow at the upper circumference of the aortic arch redirecting cardiac 
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emboli into the cerebral circulation. A large proportion of ESUS may actually be the 
consequence of fissuring of non-stenotic plaques that escape detection by carotid 
ultrasound. Further research into the role of lipids in the IS subtype is required to draw more 
definitive conclusions.  
Second, the Chinese Kadoorie Biobank Study provides clarity as to one of the most 
controversial topics in stroke medicine - the purported protective role of lipids for 
intracerebral haemorrhage (ICH). In brief, none of 61 NMR parameters (lipoprotein particle 
concentrations and composition, particle size, and apolipoproteins) exhibited a significant 
relationship with ICH despite the high incidence of ICH in the Chinese population and the 
large number of cases (1138 ICH patients) included in the analysis. There was no signal 
suggesting that low cholesterol or triglyceride levels confer a higher risk of ICH as has been 
suggested by a large-scale meta-analysis of observational studies including 1.4 million 
participants and 7960 ICH cases (18). This literature-based meta-analysis may have been 
confounded by unrecorded comorbidities that alter lipid levels (e.g. liver and renal disease, 
inflammatory diseases and malignancies), inclusion of high-risk individuals for cardiovascular 
disease who were treated with statins, and other determinants of ICH risk (e.g. alcohol 
consumption and socio-economic status) that were not rigorously assessed. This view is 
corroborated by genetic association studies demonstrating a higher risk of ICH in carriers of 
variants related to high rather than low cholesterol levels (19). Moreover, the initial finding 
of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial that 
high-dose statin therapy increases the risk for ICH appears to have been an artefact of the 
intention-to-treat principle and was not confirmed in any other RCT testing lipid-lowering 
strategies, nor in subsequent meta-analyses (20,21). Even in the setting of stroke 
thrombolysis, there was no higher risk of ICH among statin users (22). Although it is 
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premature to close this discussion, the study by Holmes and colleagues in this edition of the 
Journal adds further evidence that the proposed link between low cholesterol and ICH is a 
misconception. 
Third, now that most RCTs on HDL-C raising strategies have failed and Mendelian 
Randomization studies refute the causal role of HDL-C in CVD, research should target HDL 
composition, functionality (e.g. cholesterol efflux capacity), and other qualitative features. 
The Chinese Kadoorie Biobank Study suggests that the TG rather than the cholesterol 
content of HDL is a determinant of atherogenicity. Finally, circulating glycoprotein N-acetyl 
glucosamine residues - a glycan biomarker linked to inflammation and aging - showed one of 
the strongest associations across all three main vascular endpoints (MI, IS, and ICH).  More 
studies are required to scrutinize these associations and to further explore cause and effect.  
We are entering a new era of lipid management (12, 14-16). With a growing armamentarium 
of lipid-lowering therapies, patients can be more readily treated to achieve the 
recommended LDL-C target levels. Besides LDL-C, the therapeutic focus may broaden to 
tackle the residual CVD risk and include VLDL and TGs (3-6,23), as well also fatty acid 
composition (9, 24) and other apolipoproteins, i.e. lipoprotein (a) (10-12). It is time to 
advance NMR and mass spectrometry technologies for lipoprotein and apolipoprotein 
profiling to meet the high-throughput, low cost and standardization required for potential 
clinical use (25, 26). The application of multi–omics technologies might pave the way 
towards redefining CVD risk (27).   
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